234 filings
Page 4 of 12
8-K
akj86
18 Mar 22
Departure of Directors or Certain Officers
9:01am
8-K
20oclpuz5bm2jrgf
2 Feb 22
Termination of a Material Definitive Agreement
4:35pm
8-K
sv2otrfuzk c3n4
2 Sep 21
Clinical Trial of FB-401 for the Treatment of Atopic Dermatitis Fails to Meet Statistical Significance
4:05pm
EFFECT
brqxhddvoant0j
8 Jun 21
Notice of effectiveness
12:15am
8-K
xkrfjv1r kd
4 Jun 21
Departure of Directors or Certain Officers
4:05pm
UPLOAD
tspctof
3 Jun 21
Letter from SEC
12:00am
CORRESP
55kr6rl6dj9ejb388wb
3 Jun 21
Correspondence with SEC
12:00am
8-K
uu8v1izf z7zq5auxwdw
10 May 21
Forte Biosciences, Inc. Announces First Quarter 2021 Results and Provides a General Business Update
4:06pm
S-8
cnuo8ob0o1 mc0f7gbko
8 Apr 21
Registration of securities for employees
4:06pm
8-K
ocywe2jlak1 5pc
24 Mar 21
Forte Biosciences, Inc. Announces 4Q and Full Year 2020 Results and Provides a General Business Update
8:01am
8-K
jehqces0y3iqdo3nc7ag
10 Nov 20
Regulation FD Disclosure
4:07pm
8-K
1xnquprltsnb8f0z5oy
9 Nov 20
Forte Biosciences, Inc. Announces Third Quarter 2020 Results and Provides General Business Update
4:56pm